Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Using magnetic nanoparticles (MNPs) as a label in immunoassay (IA) possesses advantages such as high specific surface area, simple modification process. However, the catalytic activity of MNPs is low, which limits their applications in IA. The present study found it interesting that potassium ferrocyanide reacts with MNPs, leading to the in situ generation of Prussian blue. The produced Prussian blue shows high catalytic activity on a luminol chemiluminescent (CL) reaction. Therefore, a simple and sensitive immunoassay for rabbit IgG (rIgG) as model analyte using MNPs as label was developed. The CL intensity had a linear increase with the concentration of rIgG that ranged from 0.625 to 20 ng mL-1. The limit of detection was calculated to be 0.59 ng mL-1. In addition, the applicability of this method was evaluated using the standard addition method. The recovery ranged from 80.0% to 115.0%. What's more, the proposed CLIA method based on in situ generation of Prussian blue with MNPs was also applied to the detection of carcinoembryonic antigen (CEA) and hepatitis B virus (HBV)-related sequence-specific DNA. The LOD for the detection of CEA and sequence-specific DNA was estimated to be 0.28 ng mL-1 and 0.044 pmol, respectively.
 ...
PMID:In Situ Generation of Prussian Blue with Potassium Ferrocyanide to Improve the Sensitivity of Chemiluminescence Immunoassay Using Magnetic Nanoparticles as Label. 3086 57

In current observations, we investigated the clinical immunophenotypes in liver cells to assess the metastasic predisposition in advance hepatocellular carcinoma patients. In method, we harvested the clinically diagnosed data from 8 liver cancer subjects. Definitely, all patients were received standard chemotherapeutics when being confirmed as advanced liver cancer via clinical diagnosis. In parallel, biopsy liver samples were subjected to histopathological and immunoblotting assays. Representatively, clinical laboratory results showed that blood parameters resulted in notable elevations of aminotransferases (ALT, AST), hepatitis B e antibody (HBeAb), alpha-fetoprotein (APF) and carcinoembryonic antigen (CEA). In addition, immunoassays exhibited significant hepatocellular expressions of Ki-67 (cell proliferation), CD34 (angiogenesis), as well as strong production of CK8, CK10 (metastasis) in liver cells, as revealed in both the immunostaining and Western blotting analyses. Collectively, the present clinical findings elucidate that the metastasis of hepatocellular carcinoma relates to unregulated cell proliferation and angiogenesis. In particular, current representative immunophenotypes may be served as potential biomarkers for screening metastasis of advanced liver cancer.
 ...
PMID:Clinical biocharacterization of immunophenotype in hepatocellular carcinoma patients. 3196 12


<< Previous 1 2 3 4 5